[cited 2017 19th May]. Available from: http://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments/Spasticity.
Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in children, Excluding Cerebral Palsy [cited 2020 4th April]. Available from: https://www.businesswire.com/news/home/20190926005480/en/Ipsen-Announces-FDA-Approval-Dysport%C2%AE-abobotulinumtoxinA-Treatment.
Tizanidine Hydrochloride [cited 2020 26th May]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tizanidine-hydrochloride.
Tse F, Jaffe J, Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundamental & Clinical Pharmacology. 1987;1(6):479–88.
Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol. 2004;57(3):349–53.
Masareddy R, Kokate A, Shah V. Development of orodispersible tizanidine HCl tablets using spray dried coprocessed exipient bases. Indian J Pharm Sci. 2011;73(4):392–6.
Shanker G, Kumar CK, Gonugunta CSR, Kumar BV, Veerareddy PR. Formulation and evaluation of bioadhesive buccal drug delivery of tizanidine hydrochloride tablets. AAPS PharmSciTech. 2009;10(2):530–9.
Someshwar K, Chithaluru K, Ramarao T, Kumar K. Formulation and evaluation of effervescent floating tablets of tizanidine hydrochloride. Acta Pharma. 2011;61(2):217–26.
Hetal T, Bindesh P, Sneha T. A review on techniques for oral bioavailability enhancement of drugs. International Journal of Pharmaceutical Sciences Review and Research. 2010;4(3):033.
Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems–an overview. Acta Pharm Sin B. 2013;3(6):361–72.
Shrestha H, Bala R, Arora S. Lipid-based drug delivery systems. Journal of pharmaceutics. 2014;2014:1–10.
Parmar N, Singla N, Amin S, Kohli K. Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system. Colloids Surf B: Biointerfaces. 2011;86(2):327–38.
Azeem A, Rizwan M, Ahmad FJ, Iqbal Z, Khar RK, Aqil M, et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech. 2009;10(1):69–76.
Shakeel F, Haq N, El-Badry M, Alanazi FK, Alsarra IA. Ultra fine super self-nanoemulsifying drug delivery system (SNEDDS) enhanced solubility and dissolution of indomethacin. J Mol Liq. 2013;180:89–94.
Kamboj S, Rana V. Quality-by-design based development of a self-microemulsifying drug delivery system to reduce the effect of food on nelfinavir mesylate. Int J Pharm. 2016;501(1–2):311–25.
Vohra AM, Patel CV, Kumar P, Thakkar HP. Development of dual drug loaded solid self microemulsifying drug delivery system: exploring interfacial interactions using QbD coupled risk based approach. J Mol Liq. 2017;242:1156–68.
Food, Administration D. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research (CDER). 2005:7.
Ali T, Shoaib MH, Yousuf RI, Siddiqui F, Ali H, Ahmed FR, et al. Development and validation of a reverse phase high performance liquid chromatography (HPLC) method for determination of tizanidine in human plasma. Afr J Pharm Pharmacol. 2014;8(7):199–205.
Guideline IHT. Stability testing of new drug substances and products. Q1A (R2), current step. 2003;4:1–24.
capmul-multi-functional-lipids [cited 2020 4th April]. Available from: https://www.abiteccorp.com/en/product-repository/capmul-multi-functional-lipids/.
Gurram A, Deshpande PB, Kar SS, Nayak UY, Udupa N, Reddy M. Role of components in the formation of self-microemulsifying drug delivery systems. Indian J Pharm Sci. 2015;77(3):249–57.
Capmul G, Tween 20, propylene glycol [cited 2020 26th May]. Available from: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
Neusilin [cited 2020 26th May]. Available from: http://www.fujichemical.co.jp/english/newsletter/newsletter_pharma_0805.html.
Desai J, Thakkar H. Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles. J Microencapsul. 2016;33(7):669–78.
Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (part 2). Trop J Pharm Res. 2013;12(2):265–73.
Khan AA, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733.
Williams HD, Van Speybroeck M, Augustijns P, Porter CJ. Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin® US2: effect of drug type and formulation composition on in vitro pharmaceutical performance. J Pharm Sci. 2014;103(6):1734–46.